CL2019003508A1 - Anticuerpos humanos contra bet v 1 y métodos de uso de los mismos. - Google Patents

Anticuerpos humanos contra bet v 1 y métodos de uso de los mismos.

Info

Publication number
CL2019003508A1
CL2019003508A1 CL2019003508A CL2019003508A CL2019003508A1 CL 2019003508 A1 CL2019003508 A1 CL 2019003508A1 CL 2019003508 A CL2019003508 A CL 2019003508A CL 2019003508 A CL2019003508 A CL 2019003508A CL 2019003508 A1 CL2019003508 A1 CL 2019003508A1
Authority
CL
Chile
Prior art keywords
antibodies
bet
allergens
fagal
join
Prior art date
Application number
CL2019003508A
Other languages
English (en)
Inventor
Andrew J Murphy
Jamie M Orengo
Ashok T Badithe
Vishal Kamat
Yashu Liu
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2019003508A1 publication Critical patent/CL2019003508A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

EN EL PRESENTE DOCUMENTO SE PROPORCIONAN ANTICUERPOS QUE SE UNEN A ALÉRGENOS DE FAGALES, ALÉRGENOS RELACIONADOS CON FAGALES, POLEN DE ABEDUL O BET V 1, COMPOSICIONES QUE COMPRENDEN LOS ANTICUERPOS, ÁCIDOS NUCLEICOS QUE CODIFICAN LOS ANTICUERPOS Y MÉTODOS PARA USAR LOS ANTICUERPOS. SEGÚN CIERTAS FORMAS DE REALIZACIÓN, LOS ANTICUERPOS SON ANTICUERPOS MONOCLONALES COMPLETAMENTE HUMANOS QUE SE UNEN A BET V 1. LOS ANTICUERPOS SON ÚTILES PARA UNIRSE BET V 1 IN VIVO, EVITANDO ASÍ LA UNIÓN DEL ALÉRGENO A LA IGE PREFORMADA SOBRE LA SUPERFICIE DE LOS MASTOCITOS O BASÓFILOS. AL HACERLO, LOS ANTICUERPOS ACTÚAN PARA PREVENIR LA LIBERACIÓN DE HISTAMINA Y OTROS MEDIADORES INFLAMATORIOS DESDE LOS MASTOCITOS Y/O BASÓFILOS, MEJORANDO ASÍ LA RESPUESTA DESFAVORABLE A LOS ALÉRGENOS DE FAGALES EN INDIVIDUOS SENSIBILIZADOS.
CL2019003508A 2017-06-01 2019-11-29 Anticuerpos humanos contra bet v 1 y métodos de uso de los mismos. CL2019003508A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762513872P 2017-06-01 2017-06-01
US201762571696P 2017-10-12 2017-10-12
US201862662165P 2018-04-24 2018-04-24

Publications (1)

Publication Number Publication Date
CL2019003508A1 true CL2019003508A1 (es) 2020-06-19

Family

ID=62705709

Family Applications (3)

Application Number Title Priority Date Filing Date
CL2019003508A CL2019003508A1 (es) 2017-06-01 2019-11-29 Anticuerpos humanos contra bet v 1 y métodos de uso de los mismos.
CL2021002851A CL2021002851A1 (es) 2017-06-01 2021-10-29 Anticuerpos humanos contra bet v 1 o extracto de polen de abedul; composición farmacéutica que los comprende; y métodos de uso de los mismos (divisional de la solicitud 201903508)
CL2021002850A CL2021002850A1 (es) 2017-06-01 2021-10-29 Anticuerpos humanos contra bet v 1 o extracto de polen de abedul (bpe); composición farmacéutica que los comprende; y métodos de uso de los mismos (divisional de la solicitud 201903508)

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2021002851A CL2021002851A1 (es) 2017-06-01 2021-10-29 Anticuerpos humanos contra bet v 1 o extracto de polen de abedul; composición farmacéutica que los comprende; y métodos de uso de los mismos (divisional de la solicitud 201903508)
CL2021002850A CL2021002850A1 (es) 2017-06-01 2021-10-29 Anticuerpos humanos contra bet v 1 o extracto de polen de abedul (bpe); composición farmacéutica que los comprende; y métodos de uso de los mismos (divisional de la solicitud 201903508)

Country Status (17)

Country Link
US (3) US10793624B2 (es)
EP (1) EP3630814A1 (es)
JP (3) JP6963036B2 (es)
KR (3) KR102674000B1 (es)
CN (1) CN110997713B (es)
AU (2) AU2018275657B2 (es)
BR (1) BR112019025150B1 (es)
CA (1) CA3063588A1 (es)
CL (3) CL2019003508A1 (es)
CO (1) CO2019013196A2 (es)
IL (2) IL270894B2 (es)
MX (2) MX2019014430A (es)
MY (1) MY198270A (es)
NZ (1) NZ759513A (es)
PH (1) PH12019550238A1 (es)
WO (1) WO2018222854A1 (es)
ZA (1) ZA201907513B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016145206A1 (en) 2015-03-10 2016-09-15 Regeneron Pharmaceuticals, Inc. Aseptic piercing system and method
ES2919934T3 (es) 2017-05-05 2022-07-29 Regeneron Pharma Autoinyector y procedimientos de uso relacionados
CA3063588A1 (en) * 2017-06-01 2018-12-06 Regeneron Pharmaceuticals, Inc. Human antibodies to bet v 1 and methods of use thereof
CA3177918A1 (en) 2020-07-01 2022-01-06 Amanda ATANASIO Methods of treating allergy using anti-bet v 1 antibodies
CN113041271B (zh) * 2021-04-14 2022-12-27 浙江养生堂天然药物研究所有限公司 具有预防和抗过敏功效的组合物
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
EP4444348A4 (en) * 2021-12-08 2025-12-03 Iggenix Inc COMBINATIONS FOR ALLERGY THERAPY
WO2024200854A1 (en) 2023-03-31 2024-10-03 Alk-Abelló A/S Allergen binding antibodies suitable for treating tree pollen allergies
WO2024251358A1 (en) 2023-06-07 2024-12-12 Mabylon Ag Anti-allergen antibodies and uses thereof
KR20260025363A (ko) 2023-06-16 2026-02-24 리제너론 파아마슈티컬스, 인크. 의료 디바이스 패키징 및 관련 방법
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12624097B2 (en) 2023-07-03 2026-05-12 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins
WO2025075970A1 (en) 2023-10-02 2025-04-10 Regeneron Pharmaceuticals, Inc. Drug delivery device safety system
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025117894A2 (en) * 2023-11-29 2025-06-05 Medicovestor, Inc. Dimeric immunoconjugates for use in treating cancers and methods of use
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12121587B1 (en) 2023-12-26 2024-10-22 Medicovestor, Inc. Dimeric antibodies
US20250263471A1 (en) 2024-01-30 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010194A2 (de) 1992-10-27 1994-05-11 Biomay Produktions- Und Handelsgesellschaft M.B.H. MOLEKÜLFRAGMENTE (PEPTIDE) DER HAUPTALLERGENE DER POLLEN VON BÄUMEN DER ORDNUNG $i(FAGALES)
EP0675734A4 (en) 1992-12-21 1997-05-07 Tanox Biosystems Inc ALLERGY SPECIFIC, MONOCLONAL IgA ANTIBODIES AND SIMILAR PRODUCTS FOR ALLERGY TREATMENT.
EP0619323A1 (en) 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
ITMI20052517A1 (it) * 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
AT503297B1 (de) * 2006-05-18 2007-09-15 Biomay Ag Allergen-spezifische antikörper
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US10935554B2 (en) * 2013-08-23 2021-03-02 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (SIT)
CA3063588A1 (en) * 2017-06-01 2018-12-06 Regeneron Pharmaceuticals, Inc. Human antibodies to bet v 1 and methods of use thereof
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
CA3177918A1 (en) * 2020-07-01 2022-01-06 Amanda ATANASIO Methods of treating allergy using anti-bet v 1 antibodies

Also Published As

Publication number Publication date
JP2020523004A (ja) 2020-08-06
EP3630814A1 (en) 2020-04-08
IL270894B2 (en) 2023-04-01
IL298034B1 (en) 2024-01-01
JP7458453B2 (ja) 2024-03-29
JP2021112207A (ja) 2021-08-05
IL298034A (en) 2023-01-01
US20180346555A1 (en) 2018-12-06
IL298034B2 (en) 2024-05-01
IL270894A (en) 2020-01-30
NZ759513A (en) 2022-01-28
MX2019014430A (es) 2020-07-14
KR102329175B1 (ko) 2021-11-19
US20210054056A1 (en) 2021-02-25
ZA201907513B (en) 2022-04-28
CA3063588A1 (en) 2018-12-06
NZ782911A (en) 2025-08-29
KR20240096746A (ko) 2024-06-26
CO2019013196A2 (es) 2020-01-17
AU2022200272B2 (en) 2024-10-03
CN110997713B (zh) 2024-01-02
AU2018275657B2 (en) 2022-01-06
KR102878718B1 (ko) 2025-10-31
KR20210143327A (ko) 2021-11-26
US11767358B2 (en) 2023-09-26
US20240083986A1 (en) 2024-03-14
IL270894B (en) 2022-12-01
CL2021002851A1 (es) 2022-08-19
CL2021002850A1 (es) 2022-06-24
BR112019025150A2 (pt) 2020-06-23
KR20200012892A (ko) 2020-02-05
MY198270A (en) 2023-08-18
US10793624B2 (en) 2020-10-06
JP7162097B2 (ja) 2022-10-27
PH12019550238A1 (en) 2020-10-19
BR112019025150B1 (pt) 2022-11-08
KR102674000B1 (ko) 2024-06-11
AU2022200272A1 (en) 2022-02-10
CN110997713A (zh) 2020-04-10
AU2018275657A1 (en) 2019-12-19
JP2022174238A (ja) 2022-11-22
MX2023000390A (es) 2023-02-13
JP6963036B2 (ja) 2021-11-05
WO2018222854A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
CO2019013196A2 (es) Anticuerpos humanos contra bet v 1 y métodos de uso de los mismos
MX2014013371A (es) Anticuerpos humanos contra fel d1 y metodos de uso de los mismos.
DOP2023000165A (es) Anticuerpos de unión a cd3
MX2019010583A (es) Anticuerpos contra ligando 1 de muerte programada.
CR20150405A (es) Anticuerpos anti-il-17a y su uso en el tratamiento de transtornos autoinmunes e inflamatorios
CO2020012360A2 (es) Anticuerpos multiespecíficos y utilización de los mismos
CL2019000067A1 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos.
CU20160101A7 (es) Inmunoglobulina con fab en tándem
EA201600618A1 (ru) Устройство для рассеяния энергии
MX2016008472A (es) Anticuero monoclonal neutralizador de anti-il-33-humana.
MX2015009594A (es) Construcciones de anticuerpos para cdh19 y cd3.
CR20180318A (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
ECSP088751A (es) Anticuerpos contra la il-22 humana y usos para los mismos
AR097293A1 (es) Anticuerpo contra el receptor de tslp humana
UY37003A (es) Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulacion
MX382409B (es) Variantes de proteinas de unión al factor h y métodos de uso de estas.
ECSP19008417A (es) Anticuerpos con inmunogenicidad baja y usos de estos
MX2019010941A (es) Receptores de antigeno y usos de los mismos.
AR117721A2 (es) Anticuerpos humanos para fel d1 y métodos para usarlos
EA201992651A1 (ru) АНТИТЕЛА ЧЕЛОВЕКА К Bet v 1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
TH180929A (th) แอนติ-ทรานสเฟอริน รีเซพเตอร์ แอนติบอดีที่มีอาฟฟินิตี้ที่ถูกปรับให้เหมาะสม
RU2017132096A (ru) Применение липополисахарида rhodobacter capsulatus pg в качестве противоаллергического средства
TH1801000535A (th) โครงสร้างแอนติบอดีที่มีความจำเพาะแบบคู่ที่จับdll3และcd3
TH180920A (th) แอนติบอดีซึ่งจับเกะากับ fcrn สำหรับการรักษาโรคภูมิต้านตนเอง
AR094598A1 (es) Construcciones de anticuerpos para cdh19 y cd3